Background: Diabetic constipation is a common complication of diabetes mellitus(DM), which not only leads to pains of patients such as abdominal pain and abdominal distention, but increases the economic burden of patients and society. Whether external therapy of traditional Chinese medicine(TCM) an effective way to treat diabetic constipation has not yet come to a conclusion. Therefore, this study aimed to evaluate the efficacy of TCM external therapy for treating diabetic constipation. Methods: We searched 7 databases from inception to 21 December, 2021. The databases included PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), WanFang database, China Science and Technology Journal Database (VIP) and Chinese BioMedical Literature Database(CBM). All analyses were conducted by RevMan5.4 and Stata12.0. The Cochrane risk of bias assessment tool was used for quality assessment and risk of bias assessment. Results: A total of 40 RCTs were included in the meta-analysis, involving 3074 diabetic constipation patients. The results showed that TCM external therapy increased in total effective rate and weekly defecation times compared with control group. TCM external therapy also showed more reduction in defecation time, fecal traits score and FBS level than control group. Conclution: TCM external therapy effectively relieves the costive symptom of DM patients. This meta-analysis demonstrated that TCM external therapy was more effective in treating diabetic constipation patients than common therapy or routine defecation medicine. However, the quality of most included studies were low. More multicenter, randomized, double-blind, and placebo controlled clinical trials will be needed in the future.
Objective To evaluate the efficiency and toxicity of biweekly paclitaxel combined with 5-FU/leucovorin as second-line chemotherapy for advanced or recurrent gastric cancer.Methods The regimen of biweekly paclitaxel combined with 5-FU/leucovorin was used to treat 48 patients with metastatic or recurrent gastric cancer who had received one prior chemotherapy.The regimen was comprised of 3-hour intravenous infusion of 100 mg·m-2paclitaxel,2-hour infusion of 200 mg·m-2 leucovorin,intravenous bolus of 400 mg·m-25-FU,and 46 hour infusion of 5-FU 2.4 g·m-2(all given every 14 days,twice each cycle).Response rate(RR),Time to progression(TTP),overall survival(OS) and toxicity were evaluated.Results In the 48 patients,response rate was 22.9%,with a median TTP of 3.6 months and a median OS of 7.8 months.Median survival was obviously longer for patients attaining response compared with patients with partial response or stable disease(P0.05).The toxicity of chemotherapy was mild and manageable,and the most frequent adverse events were bone marrow suppression,peripheral neuropathy,alopecia,diarrhea,and muscle and joint pain.Conclusion Biweekly paclitaxel combined with 5-FU/leucovorin as second-line chemotherapy for advanced or recurrent gastric cancer leads to high response rate and mild toxicity and is deserving of further prospective study.
Mxi1 plays an important role in the regulation of cell proliferation. Mxi1-0, a Mxi1 isoform, has a different N-terminal amino acid sequence, intracellular location and expression profile from Mxi1. However, the precise role of Mxi1-0 in cell proliferation and the molecular mechanism underlying its function remain poorly understood. Here, we showed that Mxi1-0 suppression decreased the proliferation of human umbilical vein endothelial cells (HUVECs) along with cell accumulation in the G2/M phase. Mxi1-0 suppression also significantly decreased the expression and secretion of interleukin (IL-8). Neutralizing IL-8 in conditioned medium (CM) from Mxi1-0-overexpressed HUVECs significantly eliminated CM-induced proliferation of HUVECs. In addition, Mxi1-0 suppression significantly decreased the activity of MAP kinase ERK1/2. Treatment of HUVECs with U0126, an ERK1/2 signaling inhibitor, attenuated autocrine production of IL-8 induced by Mxi1-0 overexpression. On the other hand, Mxi1-0 overexpression-induced IL-8 increased the level of phosphorylated ERK1/2 in HUVECs, and such increasing was diminished in cells incubated with CM, which neutralized with anti-IL-8 antibody. Taken together, our results suggest that Mxi1-0 regulates the growth of HUVECs via the IL-8 and ERK1/2 pathways, which apparently reciprocally activate each other.
A Gram-stain-negative, strictly aerobic, rod-shaped motile bacterium with a single polar flagellum, designed strain ALS 81T, was isolated from sediment sample collected in the AiLian Bay of Weihai, China. Phylogenetic analysis based on 16SrRNA gene sequence indicated that strain ALS 81T forms a lineage within the family Alteromonadaceae that is distinct from the most closely related genera Agarivorans (93.9–94.4 % 16S rRNA gene sequence similarity), Celerinatantimonas (92.0 %) and Aliagarivorans (91.6 %). Optimum growth occurred in the presence of 3–4 % (w/v) NaCl, at pH 8.0 and at 28 °C. The major fatty acids (>10 % of total fatty acids) were iso-C16 : 0 (27.3 %), anteiso-C15 : 0 (27.0 %) and anteiso-C17 : 0 (11.2 %). The predominant polar lipids were phosphatidylethanolamine, glycolipid and four unidentified polar lipids. The DNA G+C content of strain ALS 81T calculated on the basis of the genome sequence is 43.5 mol% and the genome size is 4.5 Mbp. The predominant isoprenoid quinone is ubiquinone 8. On the basis of polyphasic analysis, strain ALS 81T is considered to represent a novel species in a novel genus of the family Alteromonadaceae , for which the name Alginatibacterium sediminis gen. nov., sp. nov. is proposed. The type strain of the type species is ALS 81T (=KCTC 62397T=MCCC 1K03481T).
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)